Consensus Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Delayed Toronto S.E. 12:33:08 2024-03-28 pm EDT 5-day change 1st Jan Change
1.41 CAD +2.17% Intraday chart for Oncolytics Biotech Inc. +1.44% -21.23%

Evolution of the average Target Price on Oncolytics Biotech Inc.

Price target over the last 5 years

History of analyst recommendation changes

a31562941c121ba201a9d9eba9279c.ncJkGZ_fWksmdZivIVE0NQ00pHp4mgEUbUzaVgsTpos.7pcsUcqRNXN1Hdv8QGNyYWlBlg4J8Ud1B36zYlxG5_j7tRNe67IYPFUN-w~dca4d54808db9210ce372857323b9f7b
HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating MT
Oncolytics Biotech Brief: Announcing Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep "Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate" MT
Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate CI
JonesTrading Initiates Oncolytics Biotech at Buy With $9 Price Target MT
Canaccord Genuity Adjusts Price Target on Oncolytics Biotech to $5 From $6, Maintains Buy Rating MT
Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting CI
Oncolytics Biotech Brief: Reporting Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting MT
Maxim Initiates Oncolytics Biotech With Buy Rating, Sets Price Target at $3 MT
RBC Capital Keeps OutperformSpeculative on Oncolytics Biotech MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk Rating, $6 TP on Oncolytics Biotech MT
ONCOLYTICS BIOTECH : HC Wainwright Starts Oncolytics Biotech at Buy With $15 Price Target MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk on Oncolytics Biotech After Q3 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.38 CAD
Average target price
7.25 CAD
Spread / Average Target
+425.36%
High Price Target
8.5 CAD
Spread / Highest target
+515.94%
Low Price Target
6 CAD
Spread / Lowest Target
+334.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Oncolytics Biotech Inc.

HC Wainwright
JonesTrading Institutional Services
Canaccord Genuity
Maxim
RBC Capital Markets
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings